BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Atezolizumab
1
Atezolizumab and bevacizumab combination in advanced hepatocellular carcinoma patients: The imperative for safety assessment studies
12/12/2024 7:29:58 AM | Browse: 171 | Download: 618
2
Downstaging of advanced hepatocellular carcinoma followed by liver transplantation using immune checkpoint inhibitors: Where do we stand?
9/3/2024 8:54:07 AM | Browse: 268 | Download: 689
3
Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report
7/2/2024 8:41:38 AM | Browse: 281 | Download: 973
4
Hepatocellular carcinoma immune microenvironment and check point inhibitors-current status
3/27/2024 1:28:19 PM | Browse: 200 | Download: 611
5
Massive bleeding from a gastric artery pseudoaneurysm in hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A case report
6/15/2023 12:09:46 PM | Browse: 464 | Download: 1423
6
Acute respiratory distress syndrome and severe pneumonitis after atezolizumab plus bevacizumab for hepatocellular carcinoma treatment: A case report
5/12/2023 9:13:35 AM | Browse: 582 | Download: 1426
7
Systemic treatment for unresectable hepatocellular carcinoma
3/10/2023 7:29:15 AM | Browse: 473 | Download: 1254
8
New perspectives in the management of small cell lung cancer
6/22/2022 8:29:42 AM | Browse: 724 | Download: 1583
9
Atezolizumab and bevacizumab as first line therapy in advanced hepatocellular carcinoma: Practical considerations in routine clinical practice
9/22/2021 8:09:41 AM | Browse: 826 | Download: 1240
10
Atezolizumab-induced anaphylactic shock in a patient with hepatocellular carcinoma undergoing immunotherapy: A case report
5/14/2021 9:21:56 AM | Browse: 791 | Download: 2144
11
Programmed cell death-1 inhibitor-related sclerosing cholangitis: A systematic review
1/16/2020 7:58:40 AM | Browse: 1164 | Download: 2230
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.